OPKO Health, Inc. (NASDAQ:OPK) Sees Significant Decrease in Short Interest

OPKO Health, Inc. (NASDAQ:OPK) saw a large decrease in short interest during the month of December. As of December 15th, there was short interest totalling 84,800,000 shares, a decrease of 14.0% from the November 30th total of 98,570,000 shares. Based on an average trading volume of 3,950,000 shares, the short-interest ratio is presently 21.5 days. Currently, 27.4% of the company’s stock are sold short.

Analyst Ratings Changes

A number of equities analysts have issued reports on OPK shares. Piper Sandler reaffirmed an “overweight” rating and set a $3.00 price objective on shares of OPKO Health in a report on Tuesday, September 17th. Barrington Research reaffirmed an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research report on Friday, November 8th. HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research report on Thursday, September 26th. Finally, StockNews.com lowered OPKO Health from a “hold” rating to a “sell” rating in a report on Thursday, December 26th.

Insider Buying and Selling

In related news, CEO Phillip Md Et Al Frost bought 125,000 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The shares were bought at an average price of $1.59 per share, with a total value of $198,750.00. Following the completion of the transaction, the chief executive officer now directly owns 212,536,477 shares in the company, valued at approximately $337,932,998.43. This represents a 0.06 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have acquired 1,304,255 shares of company stock worth $2,024,605 in the last quarter. Insiders own 47.26% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. CIBC Asset Management Inc grew its stake in shares of OPKO Health by 79.1% during the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 8,978 shares during the period. FMR LLC increased its stake in shares of OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares in the last quarter. Algert Global LLC bought a new stake in shares of OPKO Health in the second quarter valued at approximately $44,000. Orion Portfolio Solutions LLC purchased a new stake in shares of OPKO Health during the 3rd quarter valued at approximately $45,000. Finally, Private Advisor Group LLC boosted its holdings in OPKO Health by 242.7% in the 3rd quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock worth $53,000 after buying an additional 25,000 shares during the period. 64.63% of the stock is owned by institutional investors.

OPKO Health Price Performance

OPK opened at $1.47 on Wednesday. OPKO Health has a fifty-two week low of $0.85 and a fifty-two week high of $1.76. The firm has a 50-day moving average of $1.55 and a 200 day moving average of $1.49. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The firm has a market cap of $1.00 billion, a P/E ratio of -7.74 and a beta of 1.62.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.